Leveraging Cardea Field Effect Biosensing (FEB) and CRISPR-Chip™ technology, our products use highly sensitive electronic signals rather than optics or labels to accelerate research with improved accuracy and performance.

the Genome Sensor uses graphene biosensors combined with CRISPR-Chip technology to google genomes


Genome Sensor is powered by CRISPR-Chip - a Biology-gated Transistors combined with thousands of CRISPR-dcas9​ molecules.



By simply adding a small DNA sample, CRISPR immediately activates and starts scanning the genome.​
Genome Sensor uses CRISPR-Cas9 to google genomes


If CRISPR finds its target, it binds to it which creates a small charge that the highly conductive graphene surface can pick up.​

Genome Sensor connects biology directly with computer power for quick answers


The Genome Sensor receives the information and the data is immediately reported in the computer software.​

Field Effect Biosensing™

FEB is a label-free nano-electrical technology for measuring biomolecular interactions. Measuring the current across a graphene biology-gated transistor surface, any interaction or binding on the surface causes a change in conductance that a monitoring system can identify and translate to be interpreted by the user interface.  FEB is a patent-protected invention by Cardea. 


By combining thousands of CRISPR-dcas9 molecules with Cardean Transistors™, Cardea’s proprietary and patented CRISPR-Chip technology has the power to search genomes for specific sequences of interest. While the opportunities are endless, CRISPR-Chip has successfully proven Genome Sensor’s capabilities to detect genetic mutations such as sickle cell disease and Duchenne muscular dystrophy (DMD).